GleamWall
中文EN

APVO Aptevo Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1671584 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY4.0%
TTM EPS YoY100.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-239.1%
ROA-125.9%
ROIC (approx.)-1,145.2%
Asset turnover—

Leverage & solvency

Liabilities / assets71.1%
Debt / equity0.00x
Current ratio1.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$3.74M$3.70M$3.92M$3.54M$4.04M$3.33M$3.63M$3.88M
SG&A expense$2.88M$2.75M$2.91M$2.46M$3.57M$2.90M$2.85M$2.50M
Operating income-$6.61M-$6.44M-$6.84M-$6.00M-$7.61M-$6.23M-$6.48M-$6.38M
Net income-$6.55M-$6.36M-$6.70M-$5.81M-$7.55M-$6.20M-$6.41M-$6.31M
EBITDA-$6.58M-$6.41M-$6.80M-$5.92M-$7.56M-$6.18M-$6.42M-$6.31M
EPS (basic)-5.19-5.31-6.41—-40.13-151.29-1,581.81—
EPS (diluted)-5.19-5.31-6.41—-40.13-151.29-1,581.81—
Weighted avg. shares (diluted)1.80M1.20M1.06M—224,94741,0084,051—
Balance sheet
Cash & equivalents$8.27M$9.80M$14.53M$21.62M$9.41M$9.41M$2.14M$8.71M
Current assets$9.70M$10.80M$15.98M$23.08M$22.65M$11.08M$3.61M$10.66M
PP&E, net$353,000$236,000$268,000$303,000$384,000$432,000$482,000$543,000
Total assets$13.36M$14.52M$19.90M$27.19M$27.00M$15.62M$8.34M$15.59M
Current liabilities$6.46M$5.19M$4.76M$6.05M$5.61M$4.89M$5.39M$6.21M
Total liabilities$9.50M$8.48M$8.29M$9.81M$9.60M$9.10M$9.81M$10.84M
Shareholders' equity$3.86M$6.04M$11.61M$17.38M$17.39M$6.52M-$1.47M$4.75M
Shares outstanding2.67M1.42M1.20M997,83013.81M3.22M1.46M4,051
Cash flow statement
Operating cash flow-$5.69M-$5.45M-$7.96M-$5.24M-$6.69M-$7.09M-$6.58M-$5.76M
Investing cash flow-$156,000$0$0$0$0$0$0—
Financing cash flow$4.32M$726,000$871,000$5.79M$18.34M$14.36M$0$6.72M
Depreciation & amortization$39,000$32,000$35,000$81,000$49,000$49,000$61,000$71,000
Stock-based compensation$51,000$58,000$57,000$2,000$77,000-$163,000$180,000-$72,000

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.